选择性-话题@MedSci

#选择性#

173篇内容 | 3286人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=更年期女性血管舒缩症状（VMS）：选择性NK3R拮抗剂MLE-301进入临床试验, objectType=article, longId=201327, objectId=1f2c20132e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f2c20132e3c, replyNumber=0, likeNumber=51, createdTime=2020-10-27, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f2c20132e3c, moduleTitle=更年期女性血管舒缩症状（VMS）：选择性NK3R拮抗剂MLE-301进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f2c20132e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922954, encodeId=ad36192295470, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=61, createdTime=2020-10-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922950, encodeId=3b7e19229505b, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Circulation：缺血再灌注损伤时释放的内皮细胞来源的IL-18可选择性地扩增T外周辅助细胞以促进同种抗体的产生, objectType=article, longId=188240, objectId=52c3188240b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52c3188240b2, replyNumber=0, likeNumber=52, createdTime=2020-11-15, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52c3188240b2, moduleTitle=Circulation：缺血再灌注损伤时释放的内皮细胞来源的IL-18可选择性地扩增T外周辅助细胞以促进同种抗体的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52c3188240b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922963, encodeId=971b192296341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=JNNP：神经痛性肌萎缩患者肱肌选择性萎缩：束神经损伤的超声显像, objectType=article, longId=199624, objectId=e57a1996243f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57a1996243f, replyNumber=0, likeNumber=111, createdTime=2020-11-18, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57a1996243f, moduleTitle=JNNP：神经痛性肌萎缩患者肱肌选择性萎缩：束神经损伤的超声显像, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57a1996243f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922964, encodeId=5e36192296415, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , objectType=article, longId=200106, objectId=c2aa200106d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2aa200106d4, replyNumber=0, likeNumber=82, createdTime=2020-10-02, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2aa200106d4, moduleTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2aa200106d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922958, encodeId=2352192295856, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, objectType=article, longId=190747, objectId=c318190e4795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c318190e4795, replyNumber=0, likeNumber=0, createdTime=2020-06-11, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c318190e4795, moduleTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c318190e4795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增, objectType=article, longId=201064, objectId=c86e201064d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86e201064d5, replyNumber=0, likeNumber=75, createdTime=2021-08-12, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86e201064d5, moduleTitle=Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86e201064d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922959, encodeId=fa17192295948, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, objectType=article, longId=193383, objectId=4d63193383b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d63193383b1, replyNumber=0, likeNumber=79, createdTime=2020-07-06, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d63193383b1, moduleTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d63193383b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Stroke：选择性5-羟色胺再摄取抑制剂与脑出血的风险和结局, objectType=article, longId=189364, objectId=2f7218936475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7218936475, replyNumber=0, likeNumber=75, createdTime=2020-10-15, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7218936475, moduleTitle=Stroke：选择性5-羟色胺再摄取抑制剂与脑出血的风险和结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7218936475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922956, encodeId=b4701922956c8, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Arthritis Rheumatol：自身免疫性风湿病的选择性终止妊娠, objectType=article, longId=190383, objectId=3b7419038312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7419038312, replyNumber=0, likeNumber=58, createdTime=2020-08-11, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7419038312, moduleTitle=Arthritis Rheumatol：自身免疫性风湿病的选择性终止妊娠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7419038312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922947, encodeId=aa88192294e43, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析, objectType=article, longId=185442, objectId=072a18544228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=072a18544228, replyNumber=0, likeNumber=54, createdTime=2020-03-21, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=072a18544228, moduleTitle=Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=072a18544228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922967, encodeId=3eab192296e9f, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=69, createdTime=2021-01-20, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922946, encodeId=b49e192294645, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, objectType=article, longId=184532, objectId=4163184532b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4163184532b0, replyNumber=0, likeNumber=64, createdTime=2020-06-30, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4163184532b0, moduleTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4163184532b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=55, createdTime=2020-05-17, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922945, encodeId=5f7719229452a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Nat Commun:过表达重编程因子可以选择性清除白血病细胞 , objectType=article, longId=184408, objectId=976b18440809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976b18440809, replyNumber=0, likeNumber=64, createdTime=2020-03-23, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976b18440809, moduleTitle=Nat Commun:过表达重编程因子可以选择性清除白血病细胞 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976b18440809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922937, encodeId=b455192293eac, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药, objectType=article, longId=175528, objectId=64901e5528d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64901e5528d0, replyNumber=0, likeNumber=71, createdTime=2019-11-14, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64901e5528d0, moduleTitle=进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64901e5528d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922949, encodeId=a87f192294942, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长, objectType=article, longId=187870, objectId=4a7018e87076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7018e87076, replyNumber=0, likeNumber=94, createdTime=2020-05-20, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7018e87076, moduleTitle=Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7018e87076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922942, encodeId=7fd0192294281, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=Science：Pax3选择性聚腺苷酸化调控骨骼肌干细胞的动静转换, objectType=article, longId=182775, objectId=4d15182e75b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d15182e75b3, replyNumber=0, likeNumber=101, createdTime=2020-09-09, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d15182e75b3, moduleTitle=Science：Pax3选择性聚腺苷酸化调控骨骼肌干细胞的动静转换, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d15182e75b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922941, encodeId=b2001922941d0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, objectType=article, longId=181524, objectId=3d71181524a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d71181524a9, replyNumber=0, likeNumber=58, createdTime=2020-06-20, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d71181524a9, moduleTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d71181524a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1922955, encodeId=18eb192295569, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, objectTitle=**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光, objectType=article, longId=190010, objectId=9ca0190010fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ca0190010fb, replyNumber=0, likeNumber=69, createdTime=2020-12-14, rootId=0, userName=肉我只吃一口, userId=a0802500050, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ca0190010fb, moduleTitle=**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ca0190010fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

选择性

2020-05-29

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

更年期女性血管舒缩症状（VMS）：选择性NK3R拮抗剂MLE-301进入临床试验

2020-10-27

仁医06 (审核中...)

前往app查看评论内容

#选择性#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-10-05

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Circulation：缺血再灌注损伤时释放的内皮细胞来源的IL-18可选择性地扩增T外周辅助细胞以促进同种抗体的产生

2020-11-15

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

JNNP：神经痛性肌萎缩患者肱肌选择性萎缩：束神经损伤的超声显像

2020-11-18

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关

2020-10-02

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效

2020-06-11

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增

2021-08-12

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤

2020-07-06

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Stroke：选择性5-羟色胺再摄取抑制剂与脑出血的风险和结局

2020-10-15

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Arthritis Rheumatol：自身免疫性风湿病的选择性终止妊娠

2020-08-11

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析

2020-03-21

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2021-01-20

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究

2020-06-30

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-05-17

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Nat Commun:过表达重编程因子可以选择性清除白血病细胞

2020-03-23

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药

2019-11-14

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长

2020-05-20

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

Science：Pax3选择性聚腺苷酸化调控骨骼肌干细胞的动静转换

2020-09-09

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望

2020-06-20

肉我只吃一口 (审核中...)

前往app查看评论内容

#选择性#

**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光

2020-12-14

科室
- - 订阅+
  - 更多科室
工具
服务